Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study to Standardize Allergen Extracts: Determination of Biological Activity in HEP Units

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* 18-65 years old,~* a positive clinical history for inhalant allergy to at least one of the allergens to be tested,~* at least one positive prick test (mean wheal diameter = 3mm) when tested with already standardized extracts of the allergens under investigation.~* a mean wheal size of = 7mm2 obtained in a prick test with histamine dihydrochloride (10mg/ml).~* Written informed consent~Exclusion criteria: -currently suffering from allergy symptoms,~* history of systemic reactions to allergens,~* severe diseases influencing the results of the present study by discretion of the investigator,~* immunotherapy with an allergen preparation known to interfere with the allergens under investigation during the past two years,~* skin lesions in the skin test areas~* pregnancy or nursing,~* treatment with prohibited concomitant medications (antihistamines, corticosteroids, anti-depressants, neuroleptics or specific immunotherapy)~* alcohol or drug abuse,~* impaired in understanding nature, meaning and the scope of the study or are incapable of giving written informed consent,~* Participation in another clinical trial within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eight different allergens will be standardized in this study (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).